144 related articles for article (PubMed ID: 38928193)
1. A Systematic Review of the Predictive and Diagnostic Uses of Neuroinflammation Biomarkers for Epileptogenesis.
Aguilar-Castillo MJ; Cabezudo-García P; García-Martín G; Lopez-Moreno Y; Estivill-Torrús G; Ciano-Petersen NL; Oliver-Martos B; Narváez-Pelaez M; Serrano-Castro PJ
Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928193
[TBL] [Abstract][Full Text] [Related]
2. High Mobility Group Box 1 is a novel pathogenic factor and a mechanistic biomarker for epilepsy.
Ravizza T; Terrone G; Salamone A; Frigerio F; Balosso S; Antoine DJ; Vezzani A
Brain Behav Immun; 2018 Aug; 72():14-21. PubMed ID: 29031614
[TBL] [Abstract][Full Text] [Related]
3. Neuroinflammation and Proinflammatory Cytokines in Epileptogenesis.
Soltani Khaboushan A; Yazdanpanah N; Rezaei N
Mol Neurobiol; 2022 Mar; 59(3):1724-1743. PubMed ID: 35015252
[TBL] [Abstract][Full Text] [Related]
4. Serum concentration of high-mobility group box 1, Toll-like receptor 4 as biomarker in epileptic patients.
Yue Z; Tang J; Peng S; Cai X; Rong X; Yang L
Epilepsy Res; 2023 May; 192():107138. PubMed ID: 37075527
[TBL] [Abstract][Full Text] [Related]
5. High-mobility group box 1 as a predictive biomarker for drug-resistant epilepsy: A proof-of-concept study.
Walker LE; Sills GJ; Jorgensen A; Alapirtti T; Peltola J; Brodie MJ; Marson AG; Vezzani A; Pirmohamed M
Epilepsia; 2022 Jan; 63(1):e1-e6. PubMed ID: 34747496
[TBL] [Abstract][Full Text] [Related]
6. HMGB1 mediates microglia activation via the TLR4/NF-κB pathway in coriaria lactone induced epilepsy.
Shi Y; Zhang L; Teng J; Miao W
Mol Med Rep; 2018 Apr; 17(4):5125-5131. PubMed ID: 29393419
[TBL] [Abstract][Full Text] [Related]
7. TRIF contributes to epileptogenesis in temporal lobe epilepsy during TLR4 activation.
Wang FX; Yang XL; Ma YS; Wei YJ; Yang MH; Chen X; Chen B; He Q; Yang QW; Yang H; Liu SY
Brain Behav Immun; 2018 Jan; 67():65-76. PubMed ID: 28867282
[TBL] [Abstract][Full Text] [Related]
8. Relationship between Neuroglial Apoptosis and Neuroinflammation in the Epileptic Focus of the Brain and in the Blood of Patients with Drug-Resistant Epilepsy.
Sokolova TV; Zabrodskaya YM; Litovchenko AV; Paramonova NM; Kasumov VR; Kravtsova SV; Skiteva EN; Sitovskaya DA; Bazhanova ED
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293411
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological modulation of cytokines correlating neuroinflammatory cascades in epileptogenesis.
Vishwakarma S; Singh S; Singh TG
Mol Biol Rep; 2022 Feb; 49(2):1437-1452. PubMed ID: 34751915
[TBL] [Abstract][Full Text] [Related]
10. Molecular isoforms of high-mobility group box 1 are mechanistic biomarkers for epilepsy.
Walker LE; Frigerio F; Ravizza T; Ricci E; Tse K; Jenkins RE; Sills GJ; Jorgensen A; Porcu L; Thippeswamy T; Alapirtti T; Peltola J; Brodie MJ; Park BK; Marson AG; Antoine DJ; Vezzani A; Pirmohamed M
J Clin Invest; 2017 Jun; 127(6):2118-2132. PubMed ID: 28504645
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of MicroRNA-34c-5p facilitated neuroinflammation in drug-resistant epilepsy.
Fu M; Tao J; Wang D; Zhang Z; Wang X; Ji Y; Li Z
Brain Res; 2020 Dec; 1749():147130. PubMed ID: 32950487
[TBL] [Abstract][Full Text] [Related]
12. Exploring the Neuroinflammatory Pathway in Epilepsy and Cognitive Impairment: Role of HMGB1 and Translational Challenges.
Ngadimon IW; Seth EA; Shaikh MF
Front Biosci (Landmark Ed); 2024 Jun; 29(6):229. PubMed ID: 38940048
[TBL] [Abstract][Full Text] [Related]
13. CCL2/MCP-1, interleukin-8, and fractalkine/CXC3CL1: Potential biomarkers of epileptogenesis and pharmacoresistance in childhood epilepsy.
Česká K; Papež J; Ošlejšková H; Slabý O; Radová L; Loja T; Libá Z; Svěráková A; Brázdil M; Aulická Š
Eur J Paediatr Neurol; 2023 Sep; 46():48-54. PubMed ID: 37429062
[TBL] [Abstract][Full Text] [Related]
14. HMGB-1, TLR4, IL-1R1, TNF-α, and IL-1β: novel epilepsy markers?
Kamaşak T; Dilber B; Yaman SÖ; Durgut BD; Kurt T; Çoban E; Arslan EA; Şahin S; Karahan SC; Cansu A
Epileptic Disord; 2020 Apr; 22(2):183-193. PubMed ID: 32301731
[TBL] [Abstract][Full Text] [Related]
15. The Potential Therapeutic Role of the HMGB1-TLR Pathway in Epilepsy.
Wang S; Guan Y; Li T
Curr Drug Targets; 2021; 22(2):171-182. PubMed ID: 32729417
[TBL] [Abstract][Full Text] [Related]
16. Targeting oxidative stress improves disease outcomes in a rat model of acquired epilepsy.
Pauletti A; Terrone G; Shekh-Ahmad T; Salamone A; Ravizza T; Rizzi M; Pastore A; Pascente R; Liang LP; Villa BR; Balosso S; Abramov AY; van Vliet EA; Del Giudice E; Aronica E; Antoine DJ; Patel M; Walker MC; Vezzani A
Brain; 2017 Jul; 140(7):1885-1899. PubMed ID: 28575153
[TBL] [Abstract][Full Text] [Related]
17. High mobility group box 1 (HMGB1) as a novel frontier in epileptogenesis: from pathogenesis to therapeutic approaches.
Paudel YN; Semple BD; Jones NC; Othman I; Shaikh MF
J Neurochem; 2019 Dec; 151(5):542-557. PubMed ID: 30644560
[TBL] [Abstract][Full Text] [Related]
18. Inflammation in epileptogenesis after traumatic brain injury.
Webster KM; Sun M; Crack P; O'Brien TJ; Shultz SR; Semple BD
J Neuroinflammation; 2017 Jan; 14(1):10. PubMed ID: 28086980
[TBL] [Abstract][Full Text] [Related]
19. High mobility group box-1 (HMGB1) antagonist BoxA suppresses status epilepticus-induced neuroinflammatory responses associated with Toll-like receptor 2/4 down-regulation in rats.
Yu S; Zhang H; Hei Y; Yi X; Baskys A; Liu W; Long Q
Brain Res; 2019 Aug; 1717():44-51. PubMed ID: 30986405
[TBL] [Abstract][Full Text] [Related]
20. Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy.
Vezzani A; Balosso S; Ravizza T
Nat Rev Neurol; 2019 Aug; 15(8):459-472. PubMed ID: 31263255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
